A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients

• Status: Recruiting
• Trial end date: 2023-10-01
• Target enrollment: 0
• Participant gender: All

Summary

A randomized, double-blind, positive controlled phase III study to evaluate the efficacy and safety of BPI-7711 capsule in locally advanced or recurrent/metastatic treatment-naïve non-small cell lung cancer patients with EGFR mutation

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beta Pharma, Inc.
• Treatments: Gefitinib

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed non-small cell lung cancer.

• The ECOG score of performance status is 0-1.

• Locally advanced or recurrent metastatic NSCLC that has never received systemic treatment.

• According to RECIST1.1 criteria, there is at least 1 measurable lesion that has not been previously irradiated.

• Prior to enrollment, a central laboratory testing report has confirmed that the tumor has one of two common EGFR mutations positive that are sensitive to EGFR-TKI therapy, accompanied with or not accompanied with other EGFR mutation, with the exception of exon 20 insertion.

Exclusion Criteria:

• Previously received systemic treatment for locally advanced or recurrent metastatic cancer.

• Primary T790M mutation-positive patient.

• Previous interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonia requiring hormonal therapy, or any clinically proven active interstitial lung disease.

• Known active infections such as hepatitis B, hepatitis C, and human immunodeficiency virus.

• Local radiation therapy is carried out within 1 week; more than 30% bone marrow radiation therapy or extensive radiation therapy is performed within 4 weeks.

• ≤ 4 weeks from major surgery or ≤ 2 weeks from minor surgery.